We have a winner. In a two-horse race to grab the first-ever U.S. approval for a meningitis B vaccine, Pfizer has emerged victorious, nabbing the FDA's blessing Wednesday.
What's the value of Novartis' meningitis B vaccine, Bexsero, to the U.K.? It's a question the company and the country's government have been debating for months now, unable to come to terms on a reasonable price for the jab. But medical journal The BMJ might have an answer.
After initially leaving Novartis' meningitis B jab, Bexsero, off its national immunization program, the British government is now negotiating with the Swiss pharma over price--a series of events that's led a top Novartis Vaccines employee to tab the U.K. vaccination assessment system "flawed."
Let the negotiations begin. After pushing back on the price of Novartis' meningitis B vaccine, Bexsero, the U.K. is coming to the table with the Swiss drugmaker to see if it can haggle down the cost to its health system.
With Novartis and Pfizer racing for approval in a wide-open U.S. market, the Swiss pharma is taking the opportunity to expand its lead elsewhere, where its vaccine, Bexsero, has an expansive patient pool all to itself. And so far, it's going well, Novartis says.
Pfizer and Novartis have been racing to get their meningitis B vaccines to market for years. But as of Tuesday, the contest has never been closer, with both companies submitting approval applications to the FDA. Now, it's up to the agency to decide which shot gets the green light first--and first crack at the wide-open patient pool that comes with it.
Novartis' Bexsero, approved in 34 countries, was the world's first marketed vaccine to protect against the deadly meningitis B. And now, it's one step closer to becoming the first in the U.S.--that is, if a Pfizer candidate doesn't beat it to the finish line.
Australian survivors of the deadly meningococcal B strain are mounting pressure on the country's Pharmaceutical Benefits Advisory Committee to include Novartis' Bexsero, the only approved vaccine for the disease, on its national immunization plan when it meets next month.
In an announcement full of surprises from Novartis and GlaxoSmithKline, the sale of the Swiss company's vaccines division to Glaxo may have been the least surprising part.
When a U.K. advisory committee reversed its earlier guidance and recommended the country's National Health Service add Novartis' meningitis B vaccine Bexsero to its national immunization program, it did so on condition that the NHS secure a "cost-effective price" for the jab. And now, it seems the country and the Swiss company may have different ideas of what that price should be.